- Home
- CGEN vs SSSS Comparison
CGEN vs SSSS Comparison
Compare CGEN & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- SSSS
- Stock Information
- Founded
- CGEN 1993
- SSSS 2010
- Country
- CGEN Israel
- SSSS United States
- Employees
- CGEN N/A
- SSSS N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- SSSS Finance: Consumer Services
- Sector
- CGEN Health Care
- SSSS Finance
- Exchange
- CGEN Nasdaq
- SSSS Nasdaq
- Market Cap
- CGEN 167.4M
- SSSS 138.2M
- IPO Year
- CGEN 2000
- SSSS N/A
- Fundamental
- Price
- CGEN $1.64
- SSSS $7.34
- Analyst Decision
- CGEN
- SSSS Buy
- Analyst Count
- CGEN 0
- SSSS 2
- Target Price
- CGEN N/A
- SSSS $8.00
- AVG Volume (30 Days)
- CGEN 264.8K
- SSSS 291.2K
- Earning Date
- CGEN 08-05-2025
- SSSS 08-06-2025
- Dividend Yield
- CGEN N/A
- SSSS N/A
- EPS Growth
- CGEN N/A
- SSSS N/A
- EPS
- CGEN N/A
- SSSS N/A
- Revenue
- CGEN $27,589,000.00
- SSSS $3,644,430.00
- Revenue This Year
- CGEN N/A
- SSSS $5,400.03
- Revenue Next Year
- CGEN $173.80
- SSSS N/A
- P/E Ratio
- CGEN N/A
- SSSS N/A
- Revenue Growth
- CGEN N/A
- SSSS N/A
- 52 Week Low
- CGEN $1.13
- SSSS $3.52
- 52 Week High
- CGEN $2.66
- SSSS $7.83
- Technical
- Relative Strength Index (RSI)
- CGEN 54.29
- SSSS 66.84
- Support Level
- CGEN $1.65
- SSSS $7.11
- Resistance Level
- CGEN $1.83
- SSSS $7.50
- Average True Range (ATR)
- CGEN 0.10
- SSSS 0.34
- MACD
- CGEN -0.01
- SSSS -0.04
- Stochastic Oscillator
- CGEN 47.50
- SSSS 69.38
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.